LFA-1–Mediated Adhesion and Expression of the Leukemic (CD10+) Cell Populations in B-Lineage ALL Patients
| Patient No. . | CD10+ (%) . | CD10* . | LFA-1 Adhesion† . | LFA-1* . | ||
|---|---|---|---|---|---|---|
| Medium . | PMA . | KIM185 . | ||||
| d1 | 12 | + | + | ++ | ++ | ++ |
| d2 | 17 | ++ | + | ++ | ++ | ++ |
| d3 | 29 | ++ | + | ++ | ++ | ++ |
| d4 | 20 | ++ | +/− | + | ++ | ++ |
| 1‡ | 19 | +++ | +/− | ++ | +++ | ++ |
| 2 | 94 | −1-153 | +/− | + | ++ | ++ |
| 3 | 66 | ++ | +/− | + | ++ | ++ |
| 16 | 33 | + | +/− | + | ++ | ++ |
| 4 | 66 | ++ | +/− | + | ++ | ++ |
| 61-155 | 84 | + | − | + | +++ | ND |
| 7 | 79 | +++ | − | +/− | +++ | +++ |
| 8‡ | 60 | +++ | − | +/− | +++ | ++ |
| 9 | 55 | ++ | − | +/− | +++ | ++ |
| 5 | 73 | +++ | − | +/− | +++ | + |
| 10 | 79 | ++ | − | +/− | ++ | + |
| 81-154 | 24 | + | − | +/− | + | + |
| 11‡ | 53 | +++ | − | − | ++ | ++ |
| 12 | 38 | +++ | − | − | ++ | + |
| 111-154 | 28 | + | − | − | + | +/− |
| 13 | 58 | + | − | − | + | + |
| 14 | 47 | +++ | − | − | + | + |
| 15 | 37 | ++ | − | − | + | + |
| 11-154 | 47 | + | − | − | +/− | − |
| 17 | 100 | ++ | − | − | − | +/− |
| 18 | 97 | −1-153 | − | − | − | − |
| 19 | 92 | ++ | − | − | − | − |
| 20 | 47 | ++ | − | − | − | − |
| Patient No. . | CD10+ (%) . | CD10* . | LFA-1 Adhesion† . | LFA-1* . | ||
|---|---|---|---|---|---|---|
| Medium . | PMA . | KIM185 . | ||||
| d1 | 12 | + | + | ++ | ++ | ++ |
| d2 | 17 | ++ | + | ++ | ++ | ++ |
| d3 | 29 | ++ | + | ++ | ++ | ++ |
| d4 | 20 | ++ | +/− | + | ++ | ++ |
| 1‡ | 19 | +++ | +/− | ++ | +++ | ++ |
| 2 | 94 | −1-153 | +/− | + | ++ | ++ |
| 3 | 66 | ++ | +/− | + | ++ | ++ |
| 16 | 33 | + | +/− | + | ++ | ++ |
| 4 | 66 | ++ | +/− | + | ++ | ++ |
| 61-155 | 84 | + | − | + | +++ | ND |
| 7 | 79 | +++ | − | +/− | +++ | +++ |
| 8‡ | 60 | +++ | − | +/− | +++ | ++ |
| 9 | 55 | ++ | − | +/− | +++ | ++ |
| 5 | 73 | +++ | − | +/− | +++ | + |
| 10 | 79 | ++ | − | +/− | ++ | + |
| 81-154 | 24 | + | − | +/− | + | + |
| 11‡ | 53 | +++ | − | − | ++ | ++ |
| 12 | 38 | +++ | − | − | ++ | + |
| 111-154 | 28 | + | − | − | + | +/− |
| 13 | 58 | + | − | − | + | + |
| 14 | 47 | +++ | − | − | + | + |
| 15 | 37 | ++ | − | − | + | + |
| 11-154 | 47 | + | − | − | +/− | − |
| 17 | 100 | ++ | − | − | − | +/− |
| 18 | 97 | −1-153 | − | − | − | − |
| 19 | 92 | ++ | − | − | − | − |
| 20 | 47 | ++ | − | − | − | − |
Abbreviation: ND, not determined.
Expression (mean fluorescence): −, 0 to 10; +/−, 11 to 30; +, 31 to 90; ++, 91 to 150; and +++, >150 (LFA-1 expression was measured on the CD10+ cells using dual fluorescence analysis).
Adhesion (%): −, 0 to 5; +/−, 6 to 10; +, 11 to 20; ++, 21 to 50; and +++, 51 to 100.
CD10bright.
Gated by forward/side scatter. The percentage of leukemic cells was based on morphological data and immunophenotyping.
CD34+.
CD10dim.